Brief: Monte Rosa Therapeutics Announces First Participants Dosed In MRT-6160 Phase 1 Study
19/08/2024 12:46
Aug 19 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED
IN
MRT-6160 PHASE 1 STUDY
* MONTE ROSA THERAPEUTICS INC - MRT-6160 PHASE 1 CLINICAL
RESULTS
ANTICIPATED Q1 2025
Source text for Eikon: ID:nGNX1yYLTG
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million